Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
201 Leser
Artikel bewerten:
(0)

European Prenatal Genetic Testing Market Revitalised by Advancements in NGS and NIPT Technologies

Growth opportunities supported by implementation of cloud computing, collaborative business models and Big Data application, finds Frost & Sullivan

LONDON, Jan. 22,2018 /PRNewswire/ --Frost & Sullivan's latest analysis of the European prenatal genetic testing market point to advancements in technologies, such as next-generation sequencing techniques (NGS) and use of non-invasive prenatal testing (NIPT), as the key factors triggering market growth. The new research, Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021, projects that the market will reach $615.7 million by 2021 at a compound annual growth rate (CAGR) of 9.6 percent.

Frost & Sullivan expects the transitioning to NGS, implementation of cloud computing platforms, application of Big Data for in-house data interpretation and collaborative business models to open new growth opportunities. Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021 provides an analysis of key market dynamics, drivers, restraints, forecast and trends, market growth opportunities, segments to watch, and competitive analysis.

To access more information on this analysis, please click here.

"With only 60 to 70 per cent of pregnant women presently opting for prenatal testing, there is wide scope for increased penetration," said Frost & Sullivan Transformational Health Senior Industry Analyst Aarti Chitale. "Taking steps toward increasing physician and patient awareness and adoption of cutting-edge technologies such as NGS are expected to give the prenatal testing market much-needed revitalisation."

Whilst a major portion of the market is dominated by four to five United States-based participants, Aarti recommends a strong reliance on partnering with regional clinical labs and government-aided labs alongside research collaborations. Through these collaborations, market leaders will be able to penetrate the region, including Eastern European countries.

Further strategic imperatives for growth in the European prenatal genetic testing market include:

  • Providing value-added services such as genetic counselling by certified genetic counsellors or clinical geneticists;
  • Developing unique business models, including different partnership approaches such as collaborating with regional clinical labs, public centers, and hospitals;
  • Implementing pricing control strategies and adopting a centralised pricing strategy before collaborating with the local labs to ensure increased patient uptake; and
  • Focusing on technology collaboration to leverage proprietary technology platforms.

"Despite notable growth opportunities, strict regulations toward genetic testing across the European continent could hamper market growth," observes Aarti. "Moreover, the higher cost of NIPT tests, which are not consistent across different labs, could have a direct impact on the use of prenatal genetic tests."

Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021 is part of Frost & Sullivan's Transformational Health Growth Partnership Services Program.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Growth Opportunities in European Prenatal Genetic Testing Market,
Forecast to 2021
MD52-55

Contact:
Kristina Menzefricke
Corporate Communications - Frost & Sullivan, Europe
P: +44 (0)208 996 8589
E: kristina.menzefricke@frost.com
http://www.frost.com

http://ww2.frost.com
Twitter: @FS_Healthcare
LinkedIn: Transform Health

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.